Suchergebnisse - Yi‐Long Wu

Treffer weiter einschränken
  1. 1
    Prevalence of driver mutations in non-small-cell lung cancers in the People’s Republic of China

    Prevalence of driver mutations in non-small-cell lung cancers in the People’s Republic of China von Yi‐Long Wu, Lan-ying Gou

    Veröffentlicht 2014
    Volltext Volltext
    Revisão
    Zu den Favoriten
    Gespeichert in:
  2. 2
    Immunotherapy in the Asiatic population: any differences from Caucasian population?

    Immunotherapy in the Asiatic population: any differences from Caucasian population? von Lun-Xi Peng, Yi‐Long Wu

    Veröffentlicht 2018
    Volltext Volltext
    Revisão
    Zu den Favoriten
    Gespeichert in:
  3. 3
    Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in China

    Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in China von Si‐Yang Maggie Liu, Yi‐Long Wu

    Veröffentlicht 2017
    Volltext Volltext
    Revisão
    Zu den Favoriten
    Gespeichert in:
  4. 4
    Tislelizumab: an investigational anti-PD-1 antibody for the treatment of advanced non-small cell lung cancer (NSCLC)

    Tislelizumab: an investigational anti-PD-1 antibody for the treatment of advanced non-small cell lung cancer (NSCLC) von Si‐Yang Maggie Liu, Yi‐Long Wu

    Veröffentlicht 2020
    Volltext Volltext
    Revisão
    Zu den Favoriten
    Gespeichert in:
  5. 5
    The resistance mechanisms and treatment strategies for <i>EGFR</i>-mutant advanced non-small-cell lung cancer

    The resistance mechanisms and treatment strategies for <i>EGFR</i>-mutant advanced non-small-cell lung cancer von Wen‐Zhao Zhong, Qing Zhou, Yi‐Long Wu

    Veröffentlicht 2017
    Volltext Volltext
    Revisão
    Zu den Favoriten
    Gespeichert in:
  6. 6
    The emerging roles of NGS-based liquid biopsy in non-small cell lung cancer

    The emerging roles of NGS-based liquid biopsy in non-small cell lung cancer von Yi-Chen Zhang, Qing Zhou, Yi‐Long Wu

    Veröffentlicht 2017
    Volltext Volltext
    Revisão
    Zu den Favoriten
    Gespeichert in:
  7. 7
    Overcoming immune evasion with innovative multi-target approaches for glioblastoma

    Overcoming immune evasion with innovative multi-target approaches for glioblastoma von Hai Su, Peng Yin, Yi‐Long Wu, Xiaoli Zeng

    Veröffentlicht 2025
    Volltext
    Revisão
    Zu den Favoriten
    Gespeichert in:
  8. 8
    Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap)

    Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap) von Simon Dearden, James Stevens, Yi‐Long Wu, David P. Blowers

    Veröffentlicht 2013
    Volltext
    Revisão
    Zu den Favoriten
    Gespeichert in:
  9. 9
    Differences in driver genes between smoking‐related and non–smoking‐related lung cancer in the Chinese population

    Differences in driver genes between smoking‐related and non–smoking‐related lung cancer in the Chinese population von Lan-ying Gou, Feiyu Niu, Yi‐Long Wu, Wen‐Zhao Zhong

    Veröffentlicht 2015
    Volltext Volltext
    Revisão
    Zu den Favoriten
    Gespeichert in:
  10. 10
    Emerging therapies for non-small cell lung cancer

    Emerging therapies for non-small cell lung cancer von Chao Zhang, Natasha B. Leighl, Yi‐Long Wu, Wen‐Zhao Zhong

    Veröffentlicht 2019
    Volltext Volltext
    Revisão
    Zu den Favoriten
    Gespeichert in:
  11. 11
    LncRNA HOTAIR controls the expression of Rab22a by sponging miR-373 in ovarian cancer

    LncRNA HOTAIR controls the expression of Rab22a by sponging miR-373 in ovarian cancer von Zhongbao Zhang, Jiajing Cheng, Yi‐Long Wu, Jin Qiu, Yi Sun, Xiaowen Tong

    Veröffentlicht 2016
    Volltext Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  12. 12
    ADAURA: Phase III, Double-blind, Randomized Study of Osimertinib Versus Placebo in EGFR Mutation-positive Early-stage NSCLC After Complete Surgical Resection

    ADAURA: Phase III, Double-blind, Randomized Study of Osimertinib Versus Placebo in EGFR Mutation-positive Early-stage NSCLC After Complete Surgical Resection von Yi‐Long Wu, Roy S. Herbst, Helen Mann, Yuri Rukazenkov, Marcelo Marotti, Masahiro Tsuboi

    Veröffentlicht 2018
    Volltext Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  13. 13
    195TiP: Pembrolizumab (MK-3475) versus platinum-based chemotherapy for PD-L1+ NSCLC in a phase 3, randomized, open-label study: KEYNOTE-042

    195TiP: Pembrolizumab (MK-3475) versus platinum-based chemotherapy for PD-L1+ NSCLC in a phase 3, randomized, open-label study: KEYNOTE-042 von Tony Mok, Yi‐Long Wu, S. Sadowski, J. Zhang, Reshma Rangwala, Debra Kush, Gilberto Lopes

    Veröffentlicht 2016
    Volltext Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  14. 14
    P2.43: Pembrolizumab vs Platinum-Based Chemotherapy for PD-L1+ NSCLC: Phase 3, Randomized, Open-Label KEYNOTE-042 (NCT02220894)

    P2.43: Pembrolizumab vs Platinum-Based Chemotherapy for PD-L1+ NSCLC: Phase 3, Randomized, Open-Label KEYNOTE-042 (NCT02220894) von Gilberto Lopes, Yi‐Long Wu, S. Sadowski, Jin Zhang, Reshma Rangwala, Debra Kush, Tony Mok

    Veröffentlicht 2016
    Volltext Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  15. 15
    Influence of Curcumin on HOTAIR-Mediated Migration of Human Renal Cell Carcinoma Cells

    Influence of Curcumin on HOTAIR-Mediated Migration of Human Renal Cell Carcinoma Cells von Chang-Song Pei, Hongyan Wu, Fan-Tian Fan, Yi‐Long Wu, Cunsi Shen, Liqun Pan

    Veröffentlicht 2014
    Volltext Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  16. 16
    Complete mediastinal lymphadenectomy: the core component of the multidisciplinary therapy in resectable non-small cell lung cancer

    Complete mediastinal lymphadenectomy: the core component of the multidisciplinary therapy in resectable non-small cell lung cancer von Wen‐Zhao Zhong, Xue‐Ning Yang, Jianling Bai, Jin‐Ji Yang, Christian Manegold, Yi‐Long Wu

    Veröffentlicht 2008
    Volltext Volltext
    Revisão
    Zu den Favoriten
    Gespeichert in:
  17. 17
    Multiple primary malignancies involving lung cancer

    Multiple primary malignancies involving lung cancer von Feng Li, Wen‐Zhao Zhong, Feiyu Niu, Ning Zhao, Jin‐Ji Yang, Hong‐Hong Yan, Yi‐Long Wu

    Veröffentlicht 2015
    Volltext Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  18. 18
    Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy

    Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy von Bruno Coudert, Tudor‐Eliade Ciuleanu, K. Park, Yi‐Long Wu, Giuseppe Giaccone, Wolfram Brugger, P. Gopalakrishna, Federico Cappuzzo

    Veröffentlicht 2011
    Volltext Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  19. 19
    Maintenance erlotinib versus erlotinib at disease progression in patients with advanced non-small-cell lung cancer who have not progressed following platinum-based chemotherapy (IUNO study)

    Maintenance erlotinib versus erlotinib at disease progression in patients with advanced non-small-cell lung cancer who have not progressed following platinum-based chemotherapy (IU... von Saulius Cicėnas, Sarayut Lucien Geater, Petar Petrov, Yevhen Hotko, Gregory Hooper, Fan Xia, Nadejda Mudie, Yi‐Long Wu

    Veröffentlicht 2016
    Volltext Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  20. 20
    Emerging evidence and treatment paradigm of non-small cell lung cancer

    Emerging evidence and treatment paradigm of non-small cell lung cancer von Si‐Yang Maggie Liu, Mei-Mei Zheng, Yi Pan, Si‐Yang Maggie Liu, Yangqiu Li, Yi‐Long Wu

    Veröffentlicht 2023
    Volltext Volltext
    Revisão
    Zu den Favoriten
    Gespeichert in:

Suchwerkzeuge: